evidence table
Milk Thistle Blood Glucose Meta-Analysis Evidence Table
Structured evidence table for Milk Thistle Blood Glucose Meta-Analysis, generated from 2 reusable source documents in the Migaku knowledge base.
| topic | claim | evidence level | citation | source |
|---|---|---|---|---|
| Milk Thistle Blood Glucose Meta-Analysis | Conclusion Silymarin combined with lifestyle modifications is a safe and effective treatment option for reducing and normalizing liver enzyme levels in patients with NAFLD and associated metabolic syndrome. | 4 | Sukeepaisarnjaroen W (2026) | Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study. |
| Milk Thistle Blood Glucose Meta-Analysis | Background Non-alcoholic fatty liver disease (NAFLD) has now become a major global health concern. | 4 | Sukeepaisarnjaroen W (2026) | Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study. |
| Milk Thistle Blood Glucose Meta-Analysis | Lifestyle modifications are the first line of treatment; however, their effectiveness is often limited. | 4 | Sukeepaisarnjaroen W (2026) | Effectiveness of silymarin with lifestyle intervention in NAFLD and metabolic syndrome: a prospective single-arm study. |
| Milk Thistle Blood Glucose Meta-Analysis | Silymarin, extracted from the seeds of Silybum marianum (milk thistle), has been utilised in traditional medicine for many years and is recognised for its neuroprotective and hepatoprotective properties. | 4 | Sayyad M (2025) | Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. |
| Milk Thistle Blood Glucose Meta-Analysis | Existing research reveals that silymarin has potent antioxidant and anti-inflammatory effects, coupled with anti-fibrotic, anti-carcinogenic, neuro-regenerative, and immunomodulatory actions, and has broad therapeutic relevance in both neurological and hepatic disorders, albeit with the drawback of low solubility. | 4 | Sayyad M (2025) | Silymarin as a phytopharmaceutical agent: advances in mechanistic insights, formulation strategies, and pre-clinical applications. |
Source documents